Search

Vir Biotechnology Inc

Закрыт

СекторЗдравоохранение

11.7 5.31

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

10.89

Макс.

11.94

Ключевые показатели

By Trading Economics

Доход

206M

80M

Продажи

239M

239M

Прибыль на акцию

0.47

Рентабельность продаж

33.514

Сотрудники

367

EBITDA

201M

78M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+91.42% upside

Дивиденды

By Acuity

Следующий отчет о доходах

4 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

492M

2B

Предыдущая цена открытия

6.39

Предыдущая цена закрытия

11.7

Vir Biotechnology Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

9 окт. 2026 г., 20:02 UTC

Correlated Moves
Event
Social Media

Vir Biotechnology receives FDA Fast Track designation for VIR-5500, a PSMA-targeted treatment for metastatic castration-resistant prostate cancer.

8 окт. 2026 г., 21:01 UTC

Event

Vir Biotechnology receives FDA Fast Track designation for its investigational treatment VIR-5500 for late-line metastatic castration-resistant prostate cancer.

7 окт. 2026 г., 20:07 UTC

News
Social Media

Vir Biotechnology's shares fell following the announcement of David Liu as Chief Medical Officer, despite HC Wainwright reaffirming a Buy rating with a $22 price target.

6 окт. 2026 г., 20:40 UTC

Vir Biotechnology Inc has advanced in after-market trading, rebounding from earlier lows and achieving its highest cumulative return since Tuesday's close.

5 окт. 2026 г., 20:01 UTC

Vir Biotechnology Inc is trading sharply higher, reaching a cumulative return of nearly 6%, near the upper end of its one-month trading range.

2 окт. 2026 г., 20:07 UTC

Vir Biotechnology Inc shares fell sharply, continuing a decline from Thursday's close, despite rebounding earlier in the session.

1 окт. 2026 г., 20:13 UTC

Vir Biotechnology Inc is advancing in after-market trading, holding steady above its 20-day moving average with a cumulative return since Thursday's close.

30 сент. 2026 г., 22:56 UTC

Vir Biotechnology Inc traded modestly lower in after-market hours, continuing a downward trend since Wednesday's close, despite remaining above its 20-day moving average.

29 сент. 2026 г., 20:02 UTC

News

Vir Biotechnology is advancing after partnering with Astellas, securing $335 million to enhance its PRO-XTEN platform and support its Phase 3 hepatitis delta program.

25 сент. 2026 г., 19:55 UTC

Vir Biotechnology Inc shares fell, continuing a decline over the past three sessions, and remain below Thursday's close and the 20-day moving average.

24 сент. 2026 г., 20:07 UTC

Vir Biotechnology Inc's shares are declining, continuing a downward trend since Wednesday, amid notable selling pressure and unfavorable broader market conditions.

23 сент. 2026 г., 20:31 UTC

Vir Biotechnology Inc experienced a notable decline in after-market trading, reaching a low and positioned around the middle of its one-month trading range.

22 сент. 2026 г., 23:31 UTC

Vir Biotechnology Inc has seen a significant decline during after-market trading, with volatility indicating a sharp downturn since Tuesday's close.

21 сент. 2026 г., 20:31 UTC

Vir Biotechnology Inc has advanced in after-market trading, reaching its highest cumulative return since Monday's close and positioned above its 20-day moving average.

18 сент. 2026 г., 19:55 UTC

Vir Biotechnology Inc shares fell sharply, reaching their lowest point around midday and remaining notably below the 20-day moving average.

17 сент. 2026 г., 20:07 UTC

Correlated Moves

Vir Biotechnology is higher amid a biotech sector rally, supported by the SPDR S&P Biotech ETF's rise following Moderna's positive cancer vaccine results.

16 сент. 2026 г., 23:06 UTC

Vir Biotechnology Inc is trading modestly higher during after-market hours, continuing a routine pattern with limited fluctuations since Wednesday's close.

15 сент. 2026 г., 23:41 UTC

Vir Biotechnology Inc shares are lower in after-market hours, following a broader market decline linked to a drop in the New York Empire State Manufacturing Index.

14 сент. 2026 г., 20:13 UTC

Vir Biotechnology Inc shares are higher in after-market hours, continuing a trend of three consecutive sessions in the same direction. No specific news was identified.

11 сент. 2026 г., 20:08 UTC

Vir Biotechnology Inc shares are higher during Friday's session, reflecting broader market trends. The stock experienced volatility, reaching a high shortly after the open.

9 сент. 2026 г., 20:07 UTC

Vir Biotechnology Inc shares are lower today, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

3 сент. 2026 г., 19:46 UTC

Vir Biotechnology Inc shares are lower during Thursday's session, reversing early gains amid significant volatility. No specific news was identified to explain the decline.

2 сент. 2026 г., 23:16 UTC

Vir Biotechnology shares are lower in after-market trading, despite strong one-month performance. The stock remains above its 20-day moving average.

1 сент. 2026 г., 22:06 UTC

Social Media

Vir Biotechnology Inc. has a market cap of $1.6 billion and cash of $1 billion. Shares are higher in after-market trading following recent strong performance.

28 авг. 2026 г., 20:08 UTC

Vir Biotechnology Inc shares are lower today, continuing a decline since Thursday amid rising U.S. Treasury yields and broader market pressures.

27 авг. 2026 г., 20:08 UTC

Vir Biotechnology Inc shares are higher, reflecting a steady upward trend since Wednesday. Broader market conditions may be contributing to this positive movement.

26 авг. 2026 г., 20:08 UTC

Vir Biotechnology Inc is higher in Wednesday's session, continuing its upward trend since Tuesday's close, despite earlier fluctuations in price.

25 авг. 2026 г., 20:09 UTC

Social Media

Vir Biotechnology is gaining as social media discussions highlight its $1 billion cash position and potential catalysts, despite earlier session pullbacks.

24 авг. 2026 г., 21:01 UTC

Vir Biotechnology Inc. shares are trading higher in after-market hours, continuing a recent upward trend amid a rebound in the bond market and lower Treasury yields.

21 авг. 2026 г., 20:02 UTC

Correlated Moves

Vir Biotechnology Inc. shows upward momentum, reflecting significant gains since Thursday's close, amid positive trends in the healthcare sector and broader biotechnology market.

Сравнение c конкурентами

Изменение цены

Vir Biotechnology Inc Прогноз

Целевая цена

By TipRanks

91.42% рост

Прогноз на 12 месяцев

Средняя 21.286 USD  91.42%

Максимум 30 USD

Минимум 15 USD

Основано на мнении 8 аналитиков Wall Street, спрогнозировавших целевые цены для Vir Biotechnology Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

8 ratings

8

Покупка

0

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.